GlaxoSmithKline (NYSE: GSK) has received Food and Drug Administration approval for an additional use of its epilepsy drug Lamictal XR.

The additional use is for patients age 13 and over who suffer partial seizures and are taking one anti-epileptic drug. GSK’s Lamictal can now be used as a monotherapy, a process in which an additional drug is used by a patient while the original therapy is withdrawn overtime.

For more details, read here.

GSK employs some 4,000 people at its U.S. headquarters in RTP.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.